|
| Index | - | P/E | 0.25 | EPS (ttm) | 19.99 | Insider Own | 67.67% | Shs Outstand | 23.59M | Perf Week | 0.40% |
| Market Cap | 138.66M | Forward P/E | - | EPS next Y | -0.72 | Insider Trans | 0.00% | Shs Float | 9.50M | Perf Month | 23.96% |
| Income | -93.10M | PEG | - | EPS next Q | -0.59 | Inst Own | 6.80% | Short Float | 1.88% | Perf Quarter | -19.52% |
| Sales | 2.60M | P/S | 53.33 | EPS this Y | 93.90% | Inst Trans | -38.92% | Short Ratio | 0.13 | Perf Half Y | -55.41% |
| Book/sh | 1.21 | P/B | 4.19 | EPS next Y | 74.30% | ROA | - | Target Price | - | Perf Year | -54.08% |
| Cash/sh | 1.04 | P/C | 4.87 | EPS next 5Y | - | ROE | - | 52W Range | 3.51 - 31.45 | Perf YTD | 20.71% |
| Dividend | - | P/FCF | - | EPS past 5Y | -27.80% | ROI | -149.20% | 52W High | -83.88% | Beta | 1.81 |
| Dividend % | - | Quick Ratio | 1.80 | Sales past 5Y | -26.60% | Gross Margin | 36.50% | 52W Low | 44.44% | ATR | 0.50 |
| Employees | 300 | Current Ratio | 2.20 | Sales Q/Q | -25.00% | Oper. Margin | - | RSI (14) | 54.12 | Volatility | 9.05% 11.88% |
| Optionable | No | Debt/Eq | 2.09 | EPS Q/Q | 22.70% | Profit Margin | - | Rel Volume | 0.35 | Prev Close | 5.12 |
| Shortable | Yes | LT Debt/Eq | 1.89 | Earnings | - | Payout | - | Avg Volume | 1.43M | Price | 5.07 |
| Recom | 2.70 | SMA20 | 7.53% | SMA50 | 14.39% | SMA200 | -43.94% | Volume | 497,826 | Change | -0.98% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alstrom Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite